Alliance Pharma Has High Hopes For Recovering Chinese Market in 2023
Executive Summary
Alliance Pharma is hopeful the end to COVID-19 movement restrictions in China will help to boost demand for its key consumer health brands Kelo-cote and Nizoral in 2023.
You may also be interested in...
Alliance Pharma Enhances US Offering With Perrigo's Scar Treatments
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
UK Rejects Blood Glucose Health Claim For White Mulberry Supplement
The UK Nutrition and Health Claims Committee has rejected the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for Ascarit’s white mulberry-based dietary supplement.
Boiron's Sales Grow Double-Digits In 2022 Despite Difficult End To Year
French homeopathy specialist Boiron enjoyed a good 2022 after a few challenging years as a result of COVID-19 and France's decision to exclude homeopathic medicines from health insurance coverage.